Jessica Newcomb, Principal Accounting Officer of Tango Therapeutics, Inc., filed a Form 4 on November 4, 2026, disclosing two open-market sales of common stock totaling 7,031 shares executed on November 2, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • First sale: Jessica Newcomb disposed of 5,571 shares of common stock at a weighted average price of $22.2774 per share on November 2, 2026.
  • Second sale: An additional 1,460 shares were sold on the same date at a weighted average price of $22.9816 per share.
  • Price ranges: The first transaction ranged from $21.815 to $22.8149 per share; the second ranged from $22.82 to $23.8199 per share.
  • Remaining holdings: Following both transactions, Newcomb beneficially owned 52,090 shares directly, including 43,666 unvested restricted stock units (RSUs), each representing a contingent right to receive one share of common stock.
  • Trading plan: Both sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 23, 2026, according to the filing.
  • Issuer: Tango Therapeutics, Inc. trades on NASDAQ:TNGX.

Newcomb's November 2026 Share Sales Under 10b5-1 Plan

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Jessica Newcomb, serving as Principal Accounting Officer of Tango Therapeutics, Inc., carried out two separate dispositions of common stock on November 2, 2026. The first transaction involved 5,571 shares sold at a weighted average price of $22.2774, with individual sale prices ranging from $21.815 to $22.8149 per share. The second transaction covered 1,460 shares at a weighted average price of $22.9816, with prices ranging from $22.82 to $23.8199 per share.

The filing states that both transactions were executed pursuant to a Rule 10b5-1 trading plan that Newcomb adopted on June 23, 2026. The Form 4 notes that full information on the number of shares sold at each specific price is available upon request to the SEC staff, the issuer, or a security holder of the issuer.

After the two sales, Newcomb's directly held beneficial ownership stood at 52,090 shares. The filing discloses that this total includes 43,666 unvested RSUs, each representing a contingent right to receive one share of Tango Therapeutics common stock. The form was signed by Julie Fogarty as attorney-in-fact and filed on November 4, 2026.

What Was Disclosed

The filing reports two dispositions of Tango Therapeutics common stock by Principal Accounting Officer Jessica Newcomb on November 2, 2026, totaling 7,031 shares sold under a pre-established 10b5-1 plan, leaving her with 52,090 shares beneficially owned directly, including 43,666 unvested RSUs.